The intended population is approximately 30 adult GC/GEJ cancer patients who have confirmed HER2/neu overexpression since progression on trastuzumab by tumor biopsy (post-progression fresh or archival tissue, or post-progression pathology report). Here, ERBB2 is linked to neoplasm.